Semaglutide

Semaglutide 10 mg — GLP-1 Receptor Agonist for Metabolic Research

Semaglutide is a long-acting glucagon-like Glow Pura -1 (GLP-1) receptor agonist studied extensively in preclinical and clinical research for its effects on glycemic control, body weight, appetite regulation, and cardiometabolic markers. It is a synthetic analog of human GLP-1 with amino-acid substitutions and a fatty-acid side chain to extend half-life via albumin binding.

What It Is

Class: GLP-1 receptor agonist (incretin mimetic)

Concept: Designed to mimic and prolong native GLP-1 signaling involved in glucose-dependent insulin secretion and appetite regulation.

Format: Research-grade synthetic Glow Pura supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Incretin & Glucose Control: Activates GLP-1 receptors on pancreatic beta-cells to enhance glucose-dependent insulin secretion. Suppresses inappropriate glucagon secretion in hyperglycemic states in experimental models. Slows gastric emptying, contributing to lower post-prandial glucose excursions.

Appetite, Weight & Cardiometabolic Effects: Acts on GLP-1–responsive regions in the CNS to modulate appetite and satiety. Investigated for effects on body-weight reduction and fat-mass parameters in obesity models. Research interest in cardiometabolic markers including blood pressure, lipids, inflammatory indices, and liver-fat content.

Selected Research Highlights

Type 2 Diabetes Models: Semaglutide has been studied for improvements in fasting glucose, HbA1c, and post-prandial glycemic control in preclinical and clinical diabetes research.

Obesity & Weight Management: Trials and models report meaningful weight loss and appetite reduction with GLP-1 receptor agonism, including changes in caloric intake and food preference.

Cardiovascular Risk: GLP-1 RAs such as semaglutide have been investigated for effects on major adverse cardiovascular events (MACE), blood pressure, and lipid profiles.

Liver & NAFLD/NASH: Ongoing research explores impacts on liver fat, transaminases, and nonalcoholic fatty-liver disease–related endpoints.

Chemical & Handling Information

Type: Synthetic GLP-1 analog (long-acting)

Backbone: Modified human GLP-1 Glow Pura with fatty-acid side chain for albumin binding and prolonged half-life (exact modification per specification/lot).

Appearance: White to off-white lyophilized powder

Specifications

Glow Pura : Semaglutide

Amount: 10 mg per vial

Form: Lyophilized powder

Purity: ≥99% (HPLC); COA per lot available

Packaging: Sealed vials suitable for standard laboratory handling

Storage & Stability

Store lyophilized vials in a cool, dry place, protected from light. Refrigeration or freezing of the lyophilized Glow Pura is recommended for extended stability, according to laboratory SOPs.

After reconstitution, store at 2–8 °C for short-term use. For long-term storage, aliquot and freeze at -20 °C or below; avoid repeated freeze–thaw cycles.

Research use only. Not for human or veterinary use.